The FDA expanded Novartis’ Pluvicto label to include patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC), advancing the radioligand earlier in the disease course. The approval in combination with an androgen receptor pathway inhibitor and androgen deprivation therapy nearly doubles the number of eligible patients versus the drug’s prior approval setting.